Market News & Trends
InMed Pharmaceuticals Signs Non-Binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids
InMed Pharmaceuticals Inc. recently announced it has entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of….
eTheRNA immunotherapies & Quantoom Biosciences Announce Strategic Collaboration for the Development of a Novel RNA Production
eTheRNA immunotherapies NV and Quantoom Biosciences S.A. recently announced they are to collaborate on the development of a revolutionary RNA production system (RPS) for both research and GMP-grade material…..
Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes
Adocia recently announced the launch of a Phase 1 clinical study in collaboration with Dr. Ahmad Haidar, McGill University, Canada, to assess pharmacokinetic, glycemic control…
Avacta Announces AffiDX SARS-CoV-2 Antigen Lateral Flow Test Detects Delta Variant
Avacta Group plc recently announced that a study has shown that the AffiDX antigen lateral flow test detects the Delta variant of the SARS-CoV-2 virus…
CN Bio’s PhysioMimix Adopted by King’s College London to Investigate Chronic Liver Disease
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single and multi-organ microphysiological systems (MPS), recently announced that King’s College London, an internationally…
Orchard Therapeutics Announces Regulatory & Clinical Updates for Lead Gene Therapy Programs
Orchard Therapeutics recently announced several program updates for the company’s portfolio of approved and investigational hematopoietic stem cell (HSC) gene therapies. These updates follow recent…
CicloMed Announces Initiation of Phase 1B Trial of Fosciclopirox in Newly Diagnosed & Recurrent Urothelial Cancer Patients
CicloMed LLC recently announced that the Phase 1B clinical trial of fosciclopirox for the treatment of bladder cancer is now open. “We are excited to…
Addex Therapeutics Initiates Pivotal Phase 2b/3 Study With Dipraglurant for Dyskinesia Associated With Parkinson’s Disease
Addex Therapeutics Ltd recently announced that screening of patients has started for its pivotal Phase 2b/3 study with dipraglurant for dyskinesia associated with Parkinson’s disease…
Lonza Invests to Expand Mid-Scale Small Molecule Production Capacity, HPAPI Production at Nansha, China, Facility
To help pharma and biotech companies scale up production rapidly and effectively, Swiss CDMO Lonza recently announced an investment of CHF 20 million to bring flexible, mid-scale manufacturing capabilities to its API….
Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study
Crinetics Pharmaceuticals, Inc. recently announced the randomization of the first acromegaly patient in its Phase 3 clinical trial of paltusotine, PATHFNDR-1. This trial will be one of two planned Phase 3 studies assessing….
Roquette Boosts Customer Support With New Digital Pharma Marketplace
Roquette recently announced the opening of its new pharma online marketplace, powered by Knowde. The e-commerce platform will provide users….
Agios Submits MAA to EMA for Mitapivat for Treatment of Adults With Pyruvate Kinase Deficiency
Agios Pharmaceuticals, Inc. recently announced it has submitted a Marketing Authorization Application (MAA) for mitapivat to the European Medicines Agency (EMA) for the treatment of adults with pyruvate kinase….
Veru Announces the Presentation of a Phase 1b/2 Clinical Study Update for Sabizabulin
Veru Inc. recently announced updated clinical results from the ongoing Phase 1b/2 clinical study of sabizabulin (VERU-111), an oral cytoskeleton disruptor being evaluated for the…
Onconova Therapeutics Provides Update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer
Onconova Therapeutics, Inc. recently announced an update on the investigator-initiated Phase 1/2a trial of oral rigosertib plus nivolumab in advanced metastatic KRAS mutated (KRAS+) non-small…
H-CYTE Announces Publication of Positive Real-World Data Relating to the Use of Innovative Treatment to Improve Overall Lung Health
H-CYTE, Inc. recently announced the publication of its clinical observational study titled, Longitudinal Assessment of FEV1 Change Following Autologous Cellular Therapy. The study, published in…
Denali Therapeutics Announces Initiation of Phase 2 Study by Partner Sanofi
Denali Therapeutics Inc. recently announced its partner Sanofi has commenced dosing in a Phase 2 study of DNL758 (SAR443122), a peripherally-restricted small molecule inhibitor of…
Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Factor VII Deficiency
Catalyst Biosciences, Inc. recently announced the US FDA has granted Fast Track Designation for Marzeptacog alfa (activated), MarzAA, the company’s subcutaneously (SQ) administered next-generation engineered…
Idorsia Ltd Announces the Initiation of Phase 3 Registration Study of Antithrombotic Treatment for Use at the Onset of AMI Symptoms
Idorsia Ltd recently announced the initiation of the Phase 3 registration study “SOS-AMI” to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia’s P2Y12…
Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Toward Industrialization of Induced Pluripotent Stem Cell-Based Therapies
Catalent recently announced it has reached an agreement to acquire RheinCell Therapeutics GmbH, a developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs)…..
Viking Therapeutics Announces Initiation of Phase 1b Clinical Trial of VK0214 in Patients With X-ALD
Viking Therapeutics, Inc. recently announced the initiation of a Phase 1b clinical trial of VK0214, a novel small molecule agonist of the thyroid hormone receptor beta (TRb), in patients with X-linked….
